Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.

Launched by CLINICA UNIVERSIDAD DE NAVARRA, UNIVERSIDAD DE NAVARRA · Oct 10, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating the effects of a medication called octreotide during laparoscopic liver surgery for patients with liver cancer or liver tumors. The main goal is to see if octreotide can help reduce bleeding during surgery, lower the need for blood transfusions, and decrease the use of certain medications that help manage blood pressure during the procedure. Participants will be randomly assigned to receive either octreotide or a placebo (a treatment without the active drug) after they agree to join the study.

To join the trial, participants must be between 18 and 80 years old and have been diagnosed with liver lesions that require laparoscopic surgery. They should not have any allergies to octreotide and should be able to follow the study's requirements. Women who can become pregnant must have a negative pregnancy test before participating. This study is currently recruiting participants and aims to gather important information that could improve patient care during liver surgeries.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients diagnosed with hepatic lesions who are going to undergo hepatectomy via laparoscopy.
• • The patient must be between 18 and 80 years old.
• • The patient, or his/her representative, has given his/her consent to participate in the study.
• • The patient must, in the opinion of the investigator, be able to comply with all the requirements of the clinical trial.
• • The patient must not be allergic to the drug.
• Exclusion Criteria:
• • History of hypersensitivity to the drug to be administered.
• • Children under 18 years of age.
• • Urgent intervention.
• • Intervention performed in an open manner (not laparoscopic).
• • Patient's refusal to participate in the study.
• • Contraindication to receive octreotide.
• • Women of childbearing age (those women who are in the period between menarche and menopause). Having to present a negative pregnancy test to take part in the study.
• • Pregnant or lactating women, given the absence of studies of this drug in this patient profile.